Markets

Insider Trading

Hedge Funds

Retirement

Opinion

1281292 - 11759070 - 1

10 Healthcare Focused Hedge Funds and 10 Top Stock Picks

In this article, we discuss 10 healthcare focused hedge funds and 10 top stock picks. You can skip our detailed analysis of the performance of healthcare focused hedge funds and go directly to read 10 Healthcare Focused Hedge Funds and 5 Top Stock Picks.

Hedge funds resort to defensive stocks when faced with economic growth uncertainty and heightened stock market volatility. Healthcare has always been a stabilizing industry that weathers economic storms and helps portfolio managers stabilize portfolios in market peril. The fact that consumer demand for healthcare products and services will always be high in calm and chaotic economic cycles affirms why it is one of the most critical investment sectors.

Healthcare takes the defence concept a step further as many healthcare companies make it up. Right from companies that offer patient care to those that engage in the research and development of novel treatments to those that design, manufacture, and commercialize equipment’s diagnostics and tests used in the sector.

Orbimed Advisors is a healthcare-focused hedge fund that primarily invests in pharmaceutical and medical device companies as opposed to hospitals and insurance products, as is the case with others. With a portfolio worth $5.5 billion, the hedge fund runs a well-balanced portfolio made up of large healthcare companies and small-cap companies.

While diversification is an essential aspect of investing in the healthcare industry, $4.6 billion Deerfield Management is one of the hedge funds mostly tracked. The hedge fund specializes in funding R&D managing hostile takeovers and corporate transitions. It offers an opportunity to diversify holding beyond average healthcare plays.

While the overall stock market has been on an impressive run, with the S&P 500 rallying by about 12% year to date and the Nasdaq 100 up by about 36%, the same cannot be said about the healthcare sector. The S&P 500 Healthcare index, which tracks the performance of the 500 healthcare companies, is down by about 6% for the year.

Stock fund flows into the healthcare sector have swung wildly for the better part of the year as hedge funds, and investors try to adjust their portfolios per the prevailing economic situation. The underperformance in the healthcare sector has come on the US economy heating up to what the Atlanta Federal Reserve estimates as a booming expansion depicted by a 5.9% expansion in the third quarter.

A robust US economy often forces investors and hedge funds to pursue investment in other sectors. Technology stocks have always been the preferred option in times of strong economic growth and solid underlying macroeconomics. However, heading into yearend, uncertainties are increasingly cropping up, with the US Federal Reserve likely to keep interest rates higher for longer.

A high-interest rate environment poses the biggest threat to a US economy that was growing at an impressive rate amid expectations that the FED will start cutting interest rates at yearend. However, with inflation levels unlikely to drop below the recommended 2% threshold, the FED will likely stick with the high interest rates.

The prospect of the economy cooling off amid the high interest rates is high as businesses and companies struggle to access cheap capital to accelerate economic activity. Economists have already warned of the prospect of the economy plunging into recession amid the high-interest rates environment.

Likewise, the focus should always be on long-term plays as one of the ways of shrugging off the uncertainties triggered by the high-interest rate environment. Magnetar Capital is one healthcare-focused hedge fund that has perfected the art of long-term investment by sustainably harnessing alphas. Heavily invested in the healthcare sector, the hedge fund pursues market inefficiencies while staying focused on opportunities as the one presented in the healthcare sector after the recent pullback.

Farallon Capital is one of the top healthcare-focused hedge funds, as it invests nearly a third of its portfolio in healthcare plays as part of its defensive strategy, with a portfolio of about $17.9 billion. It boasts of the likes of Iqvia Holdings, Thermo Fisher Scientific and AstraZeneca in its portfolio. 

RA Capital Management, with a portfolio value of about $5.3 billion, is one healthcare-focused hedge fund positioned for any eventuality in the equity markets as it invests in companies with promising drugs and technologies. The hedge fund boasts on its portfolio the likes of Asendis Pharma and Legend Biotech Corporation.

Two Sigma Advisors, with a portfolio size of $39.2 billion, is also heavily invested in the healthcare sector as part of its quantitative analysis strategy. The quant hedge fund boasts the likes of Gilead Sciences Elevance Health and Regeneron Pharmaceuticals in its portfolio.

Escalating geopolitical tensions is another headwind likely to take a toll on investment sentiments in the equity markets. Tensions in the Middle East and Europe are already forcing hedge funds to tweak their portfolios with an increased focus on defensive plays like healthcare stocks.

“If you continue to see money flowing into healthcare then investors are using their feet to march to a more conservative posture given the uncertain outlook for where the economy goes from here,” said Bob Kalman, senior portfolio manager at Miramar Capital.

Source:pexels

Healthcare-focused hedge funds remain bullish on healthcare stocks, believing that the Federal Reserve interest rate hikes will eventually start to weigh on the economy. As jitters send shockwaves in the equity markets, investors and hedge funds are likely to be highly cautious and expected to turn their attention to defensive plays.

Glenview Capital, founded by legendary investor Larry Robins in 2001, is one hedge fund poised to navigate any turmoil in the equity market. It is one of the top healthcare-focused hedge funds, with a third of its portfolio on healthcare plays, including Universal Health Services and Tenet Healthcare. At the height of the 2009 financial crisis, the hedge fund returned 82.7% as most equities imploded.

HealthCor Management is a healthcare-focused hedge fund that has made a name for its non-impressive stock-picking plays. The hedge fund returned 4% in 2008 as the S&P 500 fell 19% as the financial crisis escalated. It is one of the most followed hedge funds as it invests two-thirds of its portfolio in the healthcare industry while diversifying the portfolio in different stocks.

Palo Alto Investors is another healthcare-focused hedge fund worth tracking for gaining insight into the direction the market is moving. The hedge fund mainly specializes in small-cap stocks in the healthcare sector. Its $1.2 billion portfolio comprises the likes of United Therapeutics, Amicus Therapeutics and Insmed Incorporated.

Lone Pine Capital, with a portfolio value of $10.91 billion, invests in public and private growth equity, including pursuing opportunities in the healthcare sector. It boasts of UnitedHealth Group and Moderna holdings as part of its investment strategy. 

10 Healthcare Focused Hedge Funds and Top Stock Picks

Our Methodology

Using Insider Monkey’s data from the second quarter of 2023, we ranked the stocks by how many hedge funds owned them.

10. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 73

Headquartered in New York, Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures and markets biopharmaceutical products. It offers medicines and vaccines for various therapeutic areas, including cardiovascular, metabolic, migraine, and women’s health.

While Pfizer Inc. (NYSE:PFE) is down by about 25% for the year, it is one of the top stock picks for healthcare-focused hedge funds. As the second quarter of this year concluded, 73 out of the 910 hedge funds in Insider Monkey’s database had acquired shares of Pfizer Inc. (NYSE:PFE). In Q3 2023, the noteworthy participant is Diamond Hill Capital, led by Ric Dillon, holding 6.60 million shares valued at $219.05 million.

9. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 74

AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. Its lead product is Humira, an injection for autoimmune intestinal Behcet’s diseases and pyoderma gangrenosum. It also offers Skyrizi for severe plaque psoriasis and Crohn’s disease. The company also provides facial injectable plastics and regenerative medicine.

AbbVie Inc. (NYSE:ABBV) is one of the top stocks for healthcare-focused hedge funds, going by the 100% gain over the past three years. By the conclusion of June 2023, 74 hedge funds, as monitored by Insider Monkey, disclosed their holdings in AbbVie Inc. (NYSE:ABBV), which is a decrease from the 75 funds in the prior quarter. The total value of these stakes exceeds $2.3 billion. Diamond Hill Capital, under the leadership of Ric Dillon, emerged as the notable holder of the company, with ownership of 1.32 million shares valued at $196.06 million.

8. Tenet Healthcare Corporation (NYSE:THC)

Number of Hedge Fund Holders: 74

Tenet Healthcare Corporation (NYSE:THC) is a healthcare company with three segments: hospitals, ambulatory care, and conifer. It operates hospitals offering acute care, operating and recovery rooms, and respiratory therapy services. It also provides intensive and critical care. 

Tenet Healthcare Corporation (NYSE:THC) remains one of the top stock picks for healthcare-focused hedge funds, as the stock is up by 12% for the year. It is one of the defensive plays for shrugging off any turmoil in the overall market on deteriorating macroeconomics.

At the close of Q2 2023, 74 out of the 910 hedge funds included in Insider Monkey’s research had allocated investments to Tenet Healthcare Corporation (NYSE:THC). In Q2 2023, Glenview Capital, managed by Larry Robbins, is the biggest shareholder of the company, with a holding of 6.4 million shares valued at $526 million.

7. The Cigna Group (NYSE:CI)

Number of Hedge Fund Holders: 74

The Cigna Group (NYSE:CI) provides insurance and related products and services in the United States. It offers various coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, speciality pharmacy distribution and care delivery. Its healthcare segment offers medical pharmacy, behavioural health, dental, and other products and services.

During the third quarter, Lee Munder Capital Group held a prominent stake in The Cigna Group (NYSE:CI), with a portfolio of 19,747 shares valued at $5.65 million. In the second quarter of 2023, a total of 74 hedge funds had invested in The Cigna Group (NYSE:CI), amassing a combined stake worth $4.07 billion.

The Cigna Group (NYSE:CI) delivered impressive Q3 results with $1.4 billion UN profit and $49 billion in revenue, affirming why 74 healthcare-focused hedge funds hold stakes.

6. Merck & Co., Inc. (NYSE:MRK)

Number of Hedge Fund Holders: 78

Merck & Co., Inc. (NYSE:MRK) is a healthcare company that offers human health pharmaceutical products in oncology, hospital acute care, immunology, and diabetes. Its animal health segment makes and sells drugs, vaccines, and services for animals.

Merck & Co., Inc. (NYSE:MRK) is up by more than 60% over the past three years, cementing its status as a top stock pick for healthcare-focused hedge funds. By June 2023, 78 of the 910 hedge funds featured in Insider Monkey’s database had acquired and held shares of Merck & Co., Inc. (NYSE:MRK). Notably, Ian Simm’s Impax Asset Management emerged as the company’s significant shareholder, holding shares valued at $80.41 million.

Click to continue reading and see 10 Healthcare Focused Hedge Funds and 5 Top Stock Picks.

Suggested articles:

Disclosure: None. 10 Healthcare Focused Hedge Funds and 10 Top Stock Picks is originally published on Insider Monkey.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.